Clinical Trials Logo

Corpus Uteri clinical trials

View clinical trials related to Corpus Uteri.

Filter by:
  • None
  • Page 1

NCT ID: NCT00587886 Active, not recruiting - Cancer Clinical Trials

Estrogen, Diet, Genetics and Endometrial Cancer

Start date: September 25, 2001
Phase:
Study type: Observational

The purpose of this study is to see how people's diets, other aspects of their lifestyles, and their individual genetic makeup affect their chances of getting endometrial cancer (cancer of the uterus). This survey will enroll several hundred women who have or have had endometrial cancer and several hundred who do not. We will compare these two groups of women to see what factors may lead to endometrial cancer.

NCT ID: NCT00277082 Completed - Lung Cancer Clinical Trials

Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung

Start date: August 2003
Phase: N/A
Study type: Observational

To determine the concentration of 9-nitrocamptothecin (9NC) in the alveolar fluid over time. 1.2. To determine the arterial concentration of 9NC administered by inhalation in comparison to venous and urine concentrations. 1.3. To determine the tumor concentration of 9NC administered by inhalation

NCT ID: NCT00250016 Withdrawn - Endometrial Cancer Clinical Trials

Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)

Start date: August 2003
Phase:
Study type: Observational

The purpose of this study is to determine the amount of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in a patients blood and tumor.

NCT ID: NCT00249990 Completed - Endometrial Cancer Clinical Trials

Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purposes of this study are: 1.1 To determine the efficacy of liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization to patients with metastatic endometrial cancer. 1.2 To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks. 1.3 To perform a pharmacology study of L9NC in the plasma and the lungs after aerosolization. A specific protocol will be written for this part.